ArticleBioorganic & medicinal chemistry letters2012
Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine.
Article in Bioorganic & medicinal chemistry letters, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 94 citations in OpenAlex.
- Resveratrol in Patients with Minimal Hepatic Encephalopathy.Nutrients · 2018Trial
- Molecular Regulation of HIV-1 Expression and Persistence Across Diverse Cellular Reservoirs.International journal of molecular sciences · 2026Review
- Mpox 2022 to 2025 Update: A Comprehensive Review on Its Complications, Transmission, Diagnosis, and Treatment.Viruses · 2025Review
- Review
- Recent Developments in Nanoparticle Formulations for Resveratrol Encapsulation as an Anticancer Agent.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Resveratrol and its analogs suppress HIV replication, oxidative stress, and inflammation in macrophages.NeuroImmune pharmacology and therapeutics · 2023Article
- Resveratrol Downmodulates Neutrophil Extracellular Trap (NET) Generation by Neutrophils in Patients with Severe COVID-19.Antioxidants (Basel, Switzerland) · 2022Article
- The potential role of resveratrol as supportive antiviral in treating conditions such as COVID-19 - A formulator's perspective.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- A Novel Cognition of Decitabine: Insights into Immunomodulation and Antiviral Effects.Molecules (Basel, Switzerland) · 2022Review
- Red Wine and Health: Approaches to Improve the Phenolic Content During Winemaking.Frontiers in nutrition · 2022Review
- Distinct Antiretroviral Mechanisms Elicited by a Viral Mutagen.Journal of molecular biology · 2021Article
- Resveratrol-loaded nanomedicines for cancer applications.Cancer reports (Hoboken, N.J.) · 2021Review
- Active Components fromInternational journal of molecular sciences · 2021Article
- NADFrontiers in molecular biosciences · 2021Review
- Phytoconstituents as Lead Compounds for Anti-Dengue Drug Discovery.Advances in experimental medicine and biology · 2021Article
- Review
- Can phytotherapy with polyphenols serve as a powerful approach for the prevention and therapy tool of novel coronavirus disease 2019 (COVID-19)?American journal of physiology. Endocrinology and metabolism · 2020Review
- Natural and nature-inspired stilbenoids as antiviral agents.European journal of medicinal chemistry · 2020Review
- Distinct dual antiviral mechanism that enhances hepatitis B virus mutagenesis and reduces viral DNA synthesis.Antiviral research · 2019Article
- Copper-Catalyzed Electrophilic Chlorocyclization Reaction Using Sodium Chloride as the Source of Electrophilic Chlorine.ACS omega · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Ribonucleotide reductase inhibitors enhance the anti-HIV-1 activities of a variety of nucleoside analogs, including those that act as chain terminators and those that increase the HIV-1 mutation rate. However the use of these ribonucleotide reductase inhibitors is limited by their associated toxicities. The hydroxylated phytostilbene resveratrol has activity in a host of systems including inhibition of ribonucleotide reductase and has minimal toxicity. Here we synthesized derivatives of resveratrol and examined them for anti-HIV-1 activity and their ability to enhance the antiviral activity of decitabine, a nucleoside analog that decreases viral replication by increasing the HIV-1 mutation rate. The data demonstrates that six of the derivatives have anti-HIV-1 activity greater than resveratrol. However, only resveratrol acted in synergy with decitabine to inhibit HIV-1 infectivity. These results reveal novel resveratrol derivatives with anti-HIV-1 activity that may have mechanisms of action that differ from the drugs currently used to treat HIV-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.